Pfizer had a relatively flat day in the market today. For many, that proved to be a surprise considering the news released by the company just yesterday. Below, we’ll talk about this news, why a rally in the value of Pfizer may be around the corner, and what binary options traders should be watching for ahead.

Pfizer Announces BLA Approval

As mentioned above, Yesterday, Pfizer had some great news to announce to the investing community. That news was that the company received United States Food and Drug Administration acceptance with regard to a recent Biologics License Application.

The application surrounded Inotuzumab ozogamicin a treatment for that was evaluated for use in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, also known as ALL. The announcement means that Pfizer may soon bring this treatment to the commercialization stage, allowing the treatment to become a revenue generator.

This treatment has the potential to be a game changer in the treatment of ALL. In fact, back in October of 2015, Pfizer was granted Breakthrough Therapy Designation by the United States Food and Drug Administration for the treatment. This put the treatment on a fast track toward approval. In fact, because of the Breakthrough Therapy Designation, Pfizer will only have to wait a maximum of 6 months from the date of acceptance for a response, rather than 10 months. In a statement, Mace Rothenberg, MD, chief development officer of Oncology in the Pfizer Global Product Development division had the following to say…

“ALL that has recurred after, or is refractory to, first-line therapy is a rapidly progressing and deadly disease… Based on the positive results of the INO-VATE 1022 Phase 3 trial, we believe inotuzumab ozogamicin, if approved, represents a new treatment option for adult patients with relapsed or refractory B-cell precursor ALL.”

Why A Big Run Upward May Be In Pfizer’s Near Future

Surprisingly, even with the incredibly positive news that was released yesterday, Pfizer did not make a run for the top. Unfortunately, the stock traded flat. Considering the positive news, I did a search and was unable to find any bad news that would be holding the company back. Unfortunately, it didn’t seem like this milestone caused much excitement.

Nonetheless, this happens occasionally. It’s not often, but it does happen. At the end of the day, sometimes investors miss the news, and in this case, I think that’s what happened. The truth is that we saw press releases about it, but when it comes to the online authors that really have the attention of investor, no one seemed to cover the news. So, as this news starts to get coverage, I’m expecting to see a bit of a reaction.

What Binary Options Traders Should Be Watching Ahead

Considering the fundamental news surrounding Pfizer at the moment, we’re likely to see quite a bit of movement ahead. However, if you want to profit from this movement, you’ll want to stay on top of the story. Make sure to follow influential players. As they pick up the story and start to form opinions, the market will likely react, creating opportunities for binary options traders.